Yaren Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of thyroid ciwon daji.
Eisai ya ce Lenvima zai zama sabon ma'auni don maganin ciwon daji na thyroid wanda ba a iya gano shi ba. Masana'antar tana da kyakkyawan fata game da Lenvima, kuma ana tsammanin cewa maganin zai zama sabon saniya tsabar kuɗi ga Eisai, tare da tallace-tallace na shekara-shekara sama da dala biliyan 1.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tumo volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
A halin yanzu, kodayake yawancin nau'in ciwon daji na thyroid ana iya bi da su, akwai 'yan zaɓuɓɓuka don magani da zarar ya yi muni. Bambance-bambancen ciwon daji na thyroid (DTC) shine mafi yawan ƙwayar cutar thyroid, kuma abin da ya faru ya karu a hankali a cikin 'yan shekarun nan.
Lenvatinib shine mai hanawa na baka da yawa mai karɓar tyrosine kinase (RTK) tare da yanayin ɗaurin labari. Baya ga hana sauran RTKs da ke cikin haɓakar ƙwayar cuta da kuma hanyoyin siginar oncogenic, kuma yana iya zaɓin hana haɓakar haɓakar haɓakar haɓakar ƙwayar cuta (VEGF) receptor kinase.
